JP2017515466A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515466A5
JP2017515466A5 JP2016562248A JP2016562248A JP2017515466A5 JP 2017515466 A5 JP2017515466 A5 JP 2017515466A5 JP 2016562248 A JP2016562248 A JP 2016562248A JP 2016562248 A JP2016562248 A JP 2016562248A JP 2017515466 A5 JP2017515466 A5 JP 2017515466A5
Authority
JP
Japan
Prior art keywords
lactamase
residue
polarity
alanine
cephalosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016562248A
Other languages
English (en)
Japanese (ja)
Other versions
JP6685925B2 (ja
JP2017515466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026457 external-priority patent/WO2015161243A2/en
Publication of JP2017515466A publication Critical patent/JP2017515466A/ja
Publication of JP2017515466A5 publication Critical patent/JP2017515466A5/ja
Application granted granted Critical
Publication of JP6685925B2 publication Critical patent/JP6685925B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016562248A 2014-04-17 2015-04-17 治療用として改善された特性を有するβ−ラクタマーゼ Expired - Fee Related JP6685925B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461980844P 2014-04-17 2014-04-17
US61/980,844 2014-04-17
US201462046627P 2014-09-05 2014-09-05
US62/046,627 2014-09-05
PCT/US2015/026457 WO2015161243A2 (en) 2014-04-17 2015-04-17 Beta-lactamases with improved properties for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019220462A Division JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Publications (3)

Publication Number Publication Date
JP2017515466A JP2017515466A (ja) 2017-06-15
JP2017515466A5 true JP2017515466A5 (enExample) 2018-05-31
JP6685925B2 JP6685925B2 (ja) 2020-04-22

Family

ID=54321063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016562248A Expired - Fee Related JP6685925B2 (ja) 2014-04-17 2015-04-17 治療用として改善された特性を有するβ−ラクタマーゼ
JP2019220462A Expired - Fee Related JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019220462A Expired - Fee Related JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Country Status (10)

Country Link
US (14) US9290754B2 (enExample)
EP (1) EP3132033B1 (enExample)
JP (2) JP6685925B2 (enExample)
KR (1) KR102360582B1 (enExample)
CN (1) CN106163546B (enExample)
AU (1) AU2015247382B2 (enExample)
BR (1) BR112016023360B1 (enExample)
CA (1) CA2942971C (enExample)
RU (1) RU2678124C2 (enExample)
WO (1) WO2015161243A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204495B1 (en) 2014-10-08 2020-04-22 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10709773B2 (en) * 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2017144495A1 (en) * 2016-02-23 2017-08-31 Da Volterra Beta-lactamase variants
US10982205B2 (en) 2016-02-23 2021-04-20 Da Volterra Beta-lactamase variants
US11517614B2 (en) 2016-06-28 2022-12-06 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
EP3829637A1 (en) 2018-08-05 2021-06-09 Da Volterra Method for improving anticancer agent efficacy
CN112689506A (zh) 2018-08-05 2021-04-20 达·沃尔泰拉公司 用于治疗移植物抗宿主疾病的组合物
CN109337889B (zh) * 2018-12-26 2020-10-02 广州白云山拜迪生物医药有限公司 一种酶活提高的金属β-内酰胺酶突变体及其构建方法
CN109576250B (zh) * 2018-12-26 2025-04-15 广州白云山拜迪生物医药有限公司 一种酶活提高的头孢菌素酶突变体及其构建方法
EP3965804B1 (en) * 2019-05-06 2025-04-02 Theriva Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes
WO2024012487A1 (en) * 2022-07-14 2024-01-18 The Hong Kong Polytechnic University Biosensor comprising a modified beta-lactamase and uses thereof
CN115433701B (zh) * 2022-11-08 2023-03-17 南京农业大学 一株变形杆菌及其菌剂和在降解头孢类抗生素中的应用
CN117701543A (zh) * 2023-12-15 2024-03-15 四川省固体废物与化学品管理中心 一种b家族内酰胺酶突变体及其固定化方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (enExample) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
EP0837925A1 (en) 1995-07-07 1998-04-29 Novo Nordisk A/S Production of proteins using bacillus incapable of sporulation
CN1363680A (zh) * 2001-01-05 2002-08-14 上海博德基因开发有限公司 一种新的多肽——β内酰胺酶20.24和编码这种多肽的多核苷酸
DK1391502T3 (da) 2001-05-29 2012-05-21 Kao Corp Værtsmikroorganismer
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
EP2216640A1 (en) * 2004-01-09 2010-08-11 Novozymes, Inc. Bacillus licheniformis chromosome
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
DE102004032995A1 (de) * 2004-07-08 2006-03-30 Henkel Kgaa Neue, sekretierte Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren
JP2008540602A (ja) 2005-05-18 2008-11-20 ダ・ボルテラ 吸着剤の結腸送達
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
CN101104858A (zh) * 2006-07-10 2008-01-16 温州医学院 一种体外定向进化获取高活力超广谱β-内酰胺酶的方法
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US20100064393A1 (en) * 2006-11-29 2010-03-11 Novozymes, Inc. Bacillus liceniformis chromosome
CN101647022B (zh) * 2007-01-31 2012-07-18 麦科罗医药科技(武汉)有限公司 描述蛋白质的构象和根据折叠、整体形状与结构序列对其进行评价的方法、系统及装置
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
US9347057B2 (en) * 2012-06-12 2016-05-24 The Johns Hopkins University Methods for efficient, expansive user-defined DNA mutagenesis

Similar Documents

Publication Publication Date Title
JP2017515466A5 (enExample)
JP2020054368A5 (enExample)
RU2012155420A (ru) Бета-лактамаза, способ ее модификации, получения и применение
US11649223B2 (en) Amino compounds for treatment of immune and inflammatory disorders
US11649229B2 (en) Amide compounds for treatment of immune and inflammatory disorders
US12091402B2 (en) Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins
US10947205B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
ES2933513T3 (es) Compuestos macrocíclicos para el tratamiento de trastornos médicos
Shahbaz Cephalosporins: pharmacology and chemistry
JP2018506286A5 (enExample)
RU2015142245A (ru) Иммуномодифицирующие частицы для лечения воспаления
JP2012115277A5 (enExample)
RU2013151303A (ru) СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
NZ718365A (en) Solid forms of ceftolozane
JP2014529399A5 (enExample)
JP2014532754A5 (enExample)
RU2014117658A (ru) Антибактериальные соединения
JP2021505620A5 (enExample)
CN102548999A (zh) 含有取代的含氮稠杂环的头孢菌素衍生物
ES2367151T3 (es) Derivados de tioxanteno como únicos agentes anti-infecciosos para el uso en el tratamiento de enfermedades infecciosas.
JP2019523236A5 (enExample)
JP2017519763A5 (enExample)
JP2007536278A5 (enExample)
RU2017130289A (ru) Ценикривирок для лечения фиброза